Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Plasma FGF23 levels were significantly elevated in CKD mice: Fgfr1: 3flox/flox, control (212.0 ± 34.2 pg/mL, n = 5) vs CKD (19531.1 ± 9232.3 pg/mL, n = 5), P < 0.001; αKlothoflox/flox, control (182.0 ± 43.6 pg/mL, n = 8) vs CKD (19949.4 ± 14188.7 pg/mL, n = 6), P < 0.01; Fgfr1: 4flox/flox, control (232.0 ± 82.7 pg/mL, n = 8) vs CKD (37005.2 ± 15197.4 pg/mL, n = 8), P < 0.001, corresponding to the levels of plasma phosphate. 1,25(OH)2D levels were also increased in CKD mice: Fgfr1: 3flox/flox, control (27.7 ± 8.5 pg/mL, n = 5) vs CKD (209.3 ± 63.8 pg/mL, n = 5), P < 0.001; αKlothoflox/flox, control (48.0 ± 15.8 pg/mL, n = 4) vs CKD (122.2 ± 37.7 pg/mL, n = 5), P < 0.01; Fgfr1: 4flox/flox, control (45.0 ± 9.5 pg/mL, n = 5) vs CKD (88.9 ± 24.0 pg/mL, n = 4), P < 0.01.
Source: Effects of Fgfr cKO and αKlotho cKO on biochemical parameters. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Animal research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
αKlothoflox and Fgfr4flox mice were generated in our laboratory using the protocols of RIKEN (Kobe, Japan), as described in (including for αKlothoflox mouse and for Fgfr4flox mouse).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease
Study design awaiting verification · Scientific Reports · 2017
Original publication title
Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease
Copyright © 2017, The Author(s)
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Secondary hyperparathyroidism, in which parathyroid hormone (PTH) is excessively secreted in response to factors such as hyperphosphataemia, hypocalcaemia, and low 1,25-dihydroxyvitamin D (1,25(OH)2D) levels, is commonly observed in patients with chronic kidney disease (CKD), and is accompanied by high levels of fibroblast growth factor 23 (FGF23). However, the effect of FGF23 on the parathyroid glands (PG) remains controversial. To bind to FGF receptors, FGF23 requires αKlotho, which is highly expressed in the PG. Here, we examined the effects of Fgfr1: 3, αKlotho, or Fgfr1: 4 ablation specifically in the PG (conditional knockout, cKO).
When mice with early to mid-stage CKD with and without cKO were compared, plasma concentrations of calcium, phosphate, FGF23, and 1,25(OH)2D did not change significantly. In contrast, plasma PTH levels, which were elevated in CKD mice, were significantly decreased in cKO mice. PG from CKD mice showed augmentation of cell proliferation, which was significantly suppressed by cKO. Parathyroid tissue cultured for 4 days showed upregulation of PTH secretion and cell proliferation in response to FGF23. Both these effects were inhibited by cKO.
These findings suggest that FGF23 is a long-term inducer of parathyroid cell proliferation and PTH secretion, and is one cause of secondary hyperparathyroidism in CKD.
Authors’ abstract
Secondary hyperparathyroidism, in which parathyroid hormone (PTH) is excessively secreted in response to factors such as hyperphosphataemia, hypocalcaemia, and low 1,25-dihydroxyvitamin D (1,25(OH)2D) levels, is commonly observed in patients with chronic kidney disease (CKD), and is accompanied by high levels of fibroblast growth factor 23 (FGF23). However, the effect of FGF23 on the parathyroid glands (PG) remains controversial. To bind to FGF receptors, FGF23 requires αKlotho, which is highly expressed in the PG. Here, we examined the effects of Fgfr1: 3, αKlotho, or Fgfr1: 4 ablation specifically in the PG (conditional knockout, cKO).
When mice with early to mid-stage CKD with and without cKO were compared, plasma concentrations of calcium, phosphate, FGF23, and 1,25(OH)2D did not change significantly. In contrast, plasma PTH levels, which were elevated in CKD mice, were significantly decreased in cKO mice. PG from CKD mice showed augmentation of cell proliferation, which was significantly suppressed by cKO. Parathyroid tissue cultured for 4 days showed upregulation of PTH secretion and cell proliferation in response to FGF23. Both these effects were inhibited by cKO.
These findings suggest that FGF23 is a long-term inducer of parathyroid cell proliferation and PTH secretion, and is one cause of secondary hyperparathyroidism in CKD.
Publication and source details
Original title: Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease
Kazuki Kawakami; Ai Takeshita; Kenryo Furushima; Masayasu Miyajima; Ikuji Hatamura; Makoto Kuro-o; Yasuhide Furuta; Kazushige Sakaguchi
Scientific Reports · 2017
a ksaka@wakayama-med.ac.jpThese authors contributed equally to the work.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T08:39:44.320426+00:00
DOI: 10.1038/srep40534 · PMC5240111